Masimo Co. (NASDAQ:MASI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Masimo Co. (NASDAQ:MASI) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $191.40.

A number of brokerages recently issued reports on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Wells Fargo & Company raised their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler raised their price target on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Finally, Raymond James raised their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th.

Masimo Trading Up 0.4 %

Shares of MASI stock opened at $170.72 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a 52-week low of $101.61 and a 52-week high of $184.51. The company has a market capitalization of $9.14 billion, a PE ratio of 117.74 and a beta of 1.02. The business’s fifty day moving average is $172.65 and its 200 day moving average is $152.54.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its holdings in shares of Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 60 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares during the period. Blue Trust Inc. increased its holdings in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Masimo by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after buying an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans increased its holdings in shares of Masimo by 0.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.